Supreme Pharmaceuticals Inc. (TSXV: FIRE) announces that 7ACRES' first month of sales exceeded $1,500,000, and that such sales will be recorded in the quarter ended September 30, 2017.
Marijuana Investing
Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Breakthrough Lipid-Based Delivery System Revolutionizes Delivery of Cannabinoids and More
Pioneering biotechnology company Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has developed a breakthrough lipid-based system that facilitates more efficient delivery of bioactive compounds—not only enhancing bio-absorption and bioavailability but also improving taste, smell and the onset of action.
Analysts Are Seeing A Bullish Move for InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF)
InMed Pharmaceuticals, Inc. (CSE: IN; OTCQB: IMLFF), has seen a strong upward trend over the past few weeks, going from a close of $.27 at the end of August to $.50 currently on the back of strong announcements, and people are taking notice.
Algae Dynamics Corp. (ADYNF) Collaborative Study Yields Possible Breakthrough in Reversing Mental Illness Symptoms Resulting from Adolescent Cannabis Use
Algae Dynamics Corp. (OTCQB: ADYNF), a company engaged in developing unique health products and pharmaceuticals that utilize hemp, cannabis and algae oils, is making international news through its current collaboration with the University of Western Ontario (now rebranded as Western University).
PotNetwork Holding, Inc. (POTN) Subsidiary Selected as Premier Sponsor of Tommy Chong’s Blazer’s Cup
PotNetwork Holding, Inc. (OTC: POTN) this morning announced that its Diamond CBD subsidiary has been selected as an exclusive premier sponsor of Tommy Chong’s Blazer’s Cup, a large cannabis festival set to take place beginning on December 2, 2017, in San Bernardino, California.
ChineseInvestors.com, Inc. (CIIX) Again Names Paul Dickman as CFO, Pursues Exploding $7.2 Billion Legal Cannabis Market
ChineseInvestors.com, Inc. (OTCQB: CIIX) announced in an 8K SEC filing that Paul Dickman has returned as its chief financial officer, effective September 25, 2017.
How InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Breakthrough Biosynthesis Works - Video
There's been a lot of focus lately on InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) breakthrough proprietary biosynthesis technology, and how it could unlock a $6 Billion Industry.
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Targets Specific Diseases with its Proprietary Biotechnologies
Vancouver, Canada-based InMed Pharmaceuticals is a preclinical biotech company that specializes in developing novel drug therapies by manufacturing cannabinoids with the potential to have a therapeutic effect on specific diseases.
Cannabis Companies Demonstrate the Diverse Nature of the Global Marijuana Market
The cannabidiol market is large and diverse; just a few years ago, it was rather small but by 2015, consumer sales had reached $202 million, according to the CBD Report published by The Hemp Business Journal. Cannabidiol sales are expected to grow to over $2 billion by 2020.
Cannabinoid Biosynthesis Poised as Potential Game-Changer in Drug Development
As the marijuana market continues its widespread growth, researchers remain merely at the threshold of exploring the manifold potential medical applications of cannabis.
SinglePoint, Inc. (SING) Enters Letter of Intent to Acquire Stake in Denver-Based Company
Specialized holding company SinglePoint, Inc. (OTC: SING) this morning announced that it has signed a Letter of Intent (“LOI”) to acquire a Denver, Colorado-based company that is approaching $1 million in annual revenue.
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Provides Update on Advancements of Proprietary Biosynthesis Technology
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning provided an update to its investors on the significant advancements in the development of its proprietary technology for the microbial biosynthesis of cannabinoids.
InMed Pharmaceuticals (CSE: IN; OTCQB: IMLFF) Continues to Make Significant Strides on Biosynthesis Program Development
InMed Pharmaceuticals (CSE: IN, OTCQB: IMLFF) a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today an update to its investors and stakeholders on the significant advancements in its proprietary technology for the microbial biosynthesis of cannabinoids..
Cannabis Wheaton Announces Kanata Earth as First Participant in Wheaton Licensing Program and Cornerstone of Its First Nations Strategy
Cannabis Wheaton Income Corp. (TSX VENTURE: CBW) welcomes Kanata Earth Inc. as the first participant in the recently announced Wheaton Licensing Program and the cornerstone of its First Nations strategy.
Production Bottleneck Spells Opportunity for Canada’s Cannabis Producers
While developments in U.S. marijuana markets have no trouble attracting headlines, many seasoned investors have discovered a more predictable method of capitalizing on the cannabis boom by turning their attention to the north.